Search hospitals
>
North Carolina
>
Durham
Duke Comprehensive Cancer Center
Claim this profile
Durham, North Carolina 27705
Global Leader in Brain Tumor
Global Leader in Solid Tumors
Conducts research for Breast Cancer
Conducts research for Lung Cancer
Conducts research for Cancer
625 reported clinical trials
36 medical researchers
Summary
Duke Comprehensive Cancer Center is a medical facility located in Durham, North Carolina. This center is recognized for care of Brain Tumor, Solid Tumors, Breast Cancer, Lung Cancer, Cancer and other specialties. Duke Comprehensive Cancer Center is involved with conducting 625 clinical trials across 402 conditions. There are 36 research doctors associated with this hospital, such as Angeles A. Secord, Harry P. Erba, Jeffrey M. Clarke, and Richard Riedel, MD.
Area of expertise
Brain Tumor
Duke Comprehensive Cancer Center has run 95 trials for Brain Tumor. Some of their research focus areas include:
Solid Tumors
Duke Comprehensive Cancer Center has run 81 trials for Solid Tumors. Some of their research focus areas include:
Top PIs
Angeles A. Secord
Duke University Medical Center
4 years of reported clinical research
Harry P. Erba
Duke University Medical Center
7 years of reported clinical research
Jeffrey M. Clarke
Duke Cancer Institute
3 years of reported clinical research
Richard Riedel, MD
Duke University
6 years of reported clinical research
Clinical Trials running at Duke Comprehensive Cancer Center
Ovarian Cancer
Breast Cancer
Cancer
Lung Cancer
Prostate Cancer
Solid Tumors
Colorectal Cancer
Fallopian Tube Cancer
Pancreatic Cancer
Brain Tumor
Mirvetuximab + Bevacizumab
for Ovarian Cancer
GLORIOSA is a Phase 3 multicenter, open label study designed to evaluate the safety and efficacy of mirvetuximab Soravtansine + Bevacizumab as maintenance therapy in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high folate receptor-alpha (FRα) expression.
Recruiting
2 awards
Phase 3
Heated Chemotherapy + Niraparib
for Ovarian Cancer
Patients will be registered prior to, during or at the completion of neoadjuvant chemotherapy given per standard institutional guidelines +/- bevacizumab on Day 1 every 21 days for 3-4 cycles. Registered patients who progress during neoadjuvant chemotherapy will not be eligible for iCRS and will be removed from the study. Following completion of neoadjuvant chemotherapy, interval cytoreductive surgery (iCRS) will be performed in the usual fashion in both arms. Patients will be randomized at the time of iCRS (iCRS must achieve no gross residual disease or no disease \>1.0 cm in largest diameter) to receive HIPEC or no HIPEC. Patients randomized to HIPEC Arm will receive a single dose of cisplatin (100mg/m2 IP over 90 minutes at 42 C) as HIPEC. After postoperative recovery patients will receive standard post-operative platinum-based combination chemotherapy. Patients randomized to surgery only (No HIPEC Arm) will receive postoperative standard chemotherapy after recovery from surgery. Both groups will receive an additional 2-3 cycles of platinum-based combination chemotherapy per standard institutional guidelines +/- bevacizumab for a maximum total of 6 cycles of chemotherapy (neoadjuvant plus post-operative cycles) followed by niraparib individualized dosing +/- bevacizumab until progression or 36 months (if no evidence of disease).
Recruiting
2 awards
Phase 3
Rina-S
for Ovarian Cancer
This phase 3 study will be conducted in different countries all over the world. The purpose of this study is to compare how well Rina-S works against platinum-resistant ovarian cancer compared to chemotherapy drugs that are already approved and used for platinum-resistant ovarian cancer. Treatment in this study could be Rina-S or it could be 1 of 4 indicated chemotherapy agents that are considered standard medical care. There is an equal (50:50) chance of getting Rina-S or an approved chemotherapy agent as treatment in this study. No one will know what treatment they are assigned to until the first dose. All participants will receive active drug; no one will be given placebo.
Recruiting
2 awards
Phase 3
4 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Duke Comprehensive Cancer Center?
Duke Comprehensive Cancer Center is a medical facility located in Durham, North Carolina. This center is recognized for care of Brain Tumor, Solid Tumors, Breast Cancer, Lung Cancer, Cancer and other specialties. Duke Comprehensive Cancer Center is involved with conducting 625 clinical trials across 402 conditions. There are 36 research doctors associated with this hospital, such as Angeles A. Secord, Harry P. Erba, Jeffrey M. Clarke, and Richard Riedel, MD.
Where is Duke Comprehensive Cancer Center located?
To reach the Duke Comprehensive Cancer Center in Durham, NC: - Take the 147 Durham Freeway Exit (Exit 279 B) from I-40, then the Elba Street/Trent Drive Exit (Exit 15 A). - Enter the left lane and turn left into the Parking Deck on your left before the next light. - For accessible transportation, use the Duke Van Service by calling 919.684.2020.
Who should I call to ask about financial aid or insurance network?
For insurance-related inquiries at Duke Comprehensive Cancer Center, contact DCU Insurance at 508.263.6978, email insurance@dcu.org, or fax 866.897.2629. For financial assistance, reach out to the Financial Relief Program at 800-723-2210. For debt and budget management, contact BALANCE at 888.456.2227.
What insurance does Duke Comprehensive Cancer Center accept?
The Duke Comprehensive Cancer Center accepts a variety of insurance plans, including commercial health insurance plans (Aetna, Blue Cross Blue Shield of North Carolina, CIGNA Healthcare of NC, Humana, Optima Health, Progyny, United Healthcare) with HMO, POS, and PPO options. Coverage extends to pharmacy and behavioral health benefits. The center also accepts exchange health insurance plans from Healthcare.gov, Medicare Advantage Plans, and Medicaid Managed Care.
What awards or recognition has Duke Comprehensive Cancer Center received?
The Duke Comprehensive Cancer Center in Durham, North Carolina, is renowned for its significant research funding and groundbreaking studies. It has received a $6,693 award from 5 for the Fight for "Dr. Anders-Cancer Research" and a $1,932,000 award from the Department of Defense for "DoD: PCRP Clinical Consortium: Duke University Clinical Research Site". The center is also recognized for its research into racial differences in breast cancer outcomes, highlighting the disparity in chemotherapy response between Black and white women for triple negative breast cancer.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.